J&J’s (JNJ) stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and uncertainty around the talc lawsuits, among others.In addition to that, broader market uncertainties and a volatile macroeconomic environment continue to hurt the stock.The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries have been affecting global stock mark ...